Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more
Magle Chemoswed Holding Ab (MAGLE) - Net Assets
Latest net assets as of September 2025: Skr531.75 Million SEK
Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has net assets worth Skr531.75 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.04 Billion) and total liabilities (Skr507.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr531.75 Million |
| % of Total Assets | 51.19% |
| Annual Growth Rate | 44.32% |
| 5-Year Change | 382.77% |
| 10-Year Change | N/A |
| Growth Volatility | 88.07 |
Magle Chemoswed Holding Ab - Net Assets Trend (2017–2024)
This chart illustrates how Magle Chemoswed Holding Ab's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Magle Chemoswed Holding Ab (2017–2024)
The table below shows the annual net assets of Magle Chemoswed Holding Ab from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr560.60 Million | +254.31% |
| 2023-12-31 | Skr158.22 Million | +7.81% |
| 2022-12-31 | Skr146.77 Million | +5.75% |
| 2021-12-31 | Skr138.79 Million | +19.52% |
| 2020-12-31 | Skr116.12 Million | +2.17% |
| 2019-12-31 | Skr113.66 Million | +124.30% |
| 2018-12-31 | Skr50.67 Million | +17.89% |
| 2017-12-31 | Skr42.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Magle Chemoswed Holding Ab's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 838.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr57.14 Million | 10.19% |
| Common Stock | Skr1.03 Million | 0.18% |
| Other Comprehensive Income | Skr-4.10 Million | -0.73% |
| Other Components | Skr506.54 Million | 90.36% |
| Total Equity | Skr560.60 Million | 100.00% |
Magle Chemoswed Holding Ab Competitors by Market Cap
The table below lists competitors of Magle Chemoswed Holding Ab ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Logistic Properties of the Americas
NYSE MKT:LPA
|
$8.23 Million |
|
Ebusco Holding N.V.
F:8J30
|
$8.23 Million |
|
Ashima Limited
NSE:ASHIMASYN
|
$8.23 Million |
|
Skandia Greenpower AS
OL:SKAND
|
$8.24 Million |
|
Ingram Micro Bilisim Sistemleri A.S.
IS:INGRM
|
$8.23 Million |
|
PESTECH International Bhd
KLSE:5219
|
$8.23 Million |
|
MCKESSON
MU:MCK
|
$8.23 Million |
|
Brooks Laboratories Limited
NSE:BROOKS
|
$8.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Magle Chemoswed Holding Ab's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 158,225,000 to 560,603,000, a change of 402,378,000 (254.3%).
- Net income of 11,936,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 2,985,000.
- Other factors increased equity by 393,427,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr11.94 Million | +2.13% |
| Other Comprehensive Income | Skr-2.98 Million | -0.53% |
| Other Changes | Skr393.43 Million | +70.18% |
| Total Change | Skr- | 254.31% |
Book Value vs Market Value Analysis
This analysis compares Magle Chemoswed Holding Ab's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.29x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.92x to 0.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr8.45 | Skr7.80 | x |
| 2018-12-31 | Skr4.98 | Skr7.80 | x |
| 2019-12-31 | Skr11.18 | Skr7.80 | x |
| 2020-12-31 | Skr15.24 | Skr7.80 | x |
| 2021-12-31 | Skr12.85 | Skr7.80 | x |
| 2022-12-31 | Skr13.59 | Skr7.80 | x |
| 2023-12-31 | Skr14.69 | Skr7.80 | x |
| 2024-12-31 | Skr27.33 | Skr7.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Magle Chemoswed Holding Ab utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.06%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.95x
- Recent ROE (2.13%) is below the historical average (3.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 11.74% | 4.48% | 0.76x | 3.44x | Skr747.80K |
| 2018 | -6.43% | -3.08% | 0.69x | 3.01x | Skr-8.33 Million |
| 2019 | 0.66% | 0.59% | 0.60x | 1.87x | Skr-10.62 Million |
| 2020 | 1.57% | 1.28% | 0.72x | 1.71x | Skr-9.79 Million |
| 2021 | 3.08% | 3.24% | 0.56x | 1.71x | Skr-9.60 Million |
| 2022 | 6.23% | 6.28% | 0.58x | 1.72x | Skr-5.53 Million |
| 2023 | 7.69% | 7.14% | 0.62x | 1.73x | Skr-3.65 Million |
| 2024 | 2.13% | 5.06% | 0.22x | 1.95x | Skr-44.12 Million |
Industry Comparison
This section compares Magle Chemoswed Holding Ab's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Magle Chemoswed Holding Ab (MAGLE) | Skr531.75 Million | 11.74% | 0.95x | $8.23 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |